Putnam Investments’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-82,549
| Closed | -$14.2M | – | 1223 |
|
|
2021
Q3 | $14.2M | Sell |
82,549
-143,456
| -63% | -$18.8M | 0.02% | 290 |
|
|
2021
Q2 | $28.4M | Sell |
226,005
-23,700
| -9% | -$2.99M | 0.04% | 212 |
|
|
2021
Q1 | $33.9M | Sell |
249,705
-34,770
| -12% | -$4.49M | 0.06% | 203 |
|
|
2020
Q4 | $36.4M | Sell |
284,475
-418
| -0.1% | -$49K | 0.06% | 186 |
|
|
2020
Q3 | $32.1M | Buy |
284,893
+40,000
| +16% | +$3.98M | 0.06% | 191 |
|
|
2020
Q2 | $23.3M | Buy |
244,893
+82,146
| +50% | +$7.92M | 0.05% | 216 |
|
|
2020
Q1 | $14.6M | Buy |
162,747
+70,172
| +76% | +$5.45M | 0.04% | 258 |
|
|
2019
Q4 | $4.91M | Buy |
92,575
+22,471
| +32% | +$1.02M | 0.01% | 509 |
|
|
2019
Q3 | $2.77M | Buy |
70,104
+157
| +0.2% | +$6.81K | 0.01% | 655 |
|
|
2019
Q2 | $2.87M | Hold |
69,947
| – | – | 0.01% | 663 |
|
|
2019
Q1 | $3.26M | Buy |
69,947
+67
| +0.1% | +$2.94K | 0.01% | 615 |
|
|
2018
Q4 | $3.04M | Buy |
69,880
+4,896
| +8% | +$245K | 0.01% | 563 |
|
|
2018
Q3 | $3.72M | Buy |
64,984
+39,080
| +151% | +$1.92M | 0.01% | 647 |
|
|
2018
Q2 | $1.26M | Sell |
25,904
-2,684
| -9% | -$97.8K | ﹤0.01% | 820 |
|
|
2018
Q1 | $1.12M | Buy |
28,588
+192
| +0.7% | +$8.16K | ﹤0.01% | 843 |
|
|
2017
Q4 | $1.21M | Sell |
28,396
-14,232
| -33% | -$534K | ﹤0.01% | 867 |
|
|
2017
Q3 | $1.59M | Buy |
42,628
+12,614
| +42% | +$438K | ﹤0.01% | 828 |
|
|
2017
Q2 | $912K | Sell |
30,014
-106,786
| -78% | -$3.09M | ﹤0.01% | 912 |
|
|
2017
Q1 | $3.62M | Sell |
136,800
-1,505
| -1% | -$39.7K | 0.01% | 718 |
|
|
2016
Q4 | $3.53M | Sell |
138,305
-748
| -0.5% | -$23.7K | 0.01% | 702 |
|
|
2016
Q3 | $5.03M | Buy |
139,053
+14,053
| +11% | +$466K | 0.01% | 571 |
|
|
2016
Q2 | $4.25M | Hold |
125,000
| – | – | 0.01% | 701 |
|
|
2016
Q1 | $3.3M | Hold |
125,000
| – | – | 0.01% | 803 |
|
|
2015
Q4 | $6.09M | Sell |
125,000
-472
| -0.4% | -$17K | 0.01% | 595 |
|
|
2015
Q3 | $3.12M | Hold |
125,472
| – | – | 0.01% | 845 |
|
|
2015
Q2 | $3.97M | Buy |
+125,472
| New | +$4.05M | 0.01% | 823 |
|
Putnam Investments's XLRN Position: Q4 2021 in Review
Putnam Investments sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 82,549 shares — an estimated $14.2M sold.
Putnam Investments first reported a position in XLRN in Q2 2015 and held it in 26 quarters. The position peaked at $36.4M in Q4 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Putnam Investments reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Putnam Investments sold 82,549 Acceleron Pharma shares in Q4 2021, an estimated $14.2M.
- Putnam Investments first reported a position in Acceleron Pharma in Q2 2015 and held it in 26 quarters.
- Putnam Investments's Acceleron Pharma position peaked at $36.4M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Putnam Investments's 13F filing for Q4 2021, filed 14 Feb 2022.